Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects

Journal of Clinical Pharmacology

Volumn 39, Issue 2, 1999, Pages 161-165

  Jung, Donald ^a,b   Griffy, Kay ^a   Dorr, Albert ^a  

^a Roche Global Development   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; FOOD DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; FASTING; FOOD-DRUG INTERACTIONS; GANCICLOVIR; HIV SEROPOSITIVITY; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED;

EID: 0032936463     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007714     Document Type: Article

References (8)

1. Spector SA, Busch DF, Follansbee S, Squires K, Lalezari JP, Jacobson MA, Jung D, Shadman A, Mastre B, Buhles W, Drew WL, AIDS Clinical Trials Group, Cytomegalovirus Cooperative Study Group: Pharmacokinetic, safety and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995;171:1431-1437.
2. Jacobson MA, deMiranda P, Cederberg DM, Burnette T, Cobb E, Brody HR, Mills J: Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother 1987;31:1251-1254.
3. Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB: Ganciclovir absolute bioavailability after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 1996;17:425-432.
4. Lavelle J, Follansbee, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Connor J: Effect of food on the relative bioavailability of oral ganciclovir. J Clin Pharmacol 1996;36:238-241.
5. Jung D, Griffy K, Wong R, Colburn W, Hulse J: Bioavailability and dose proportionality of oral ganciclovir after ascending multiple doses in HIV positive subjects. J Clin Pharmacol: (in press).
6. Welling PG: Interactions affecting drug absorption. Clin Pharmacokinet 1984;9:404-434.
7. Wilson CG, Washington N, Hardy JG, Bond SW: The influence of food on the absorption of acyclovir: a pharmacokinetic and scintigraphic assessment. Int J Pharmaceutics 1987;38:221-225.
8. Lalezari JP, Friedberg D, Bissett J, Giordano M, Hardy D, Drew WL, Buhles W, Stempien MJ, Robinson C, Jung D for the Roche Cooperative Oral Ganciclovir Study Group: High dose oral ganciclovir treatment for cytomegalovirus retinitis: a randomized dose response study. Study GANs2226. Palo Alto, CA: Roche Global Development, 1996.